Business Context and Reporting Period
This Form 8-K Current Report was filed by Prothena Corporation plc on March 25, 2022. The registrant is incorporated in Ireland and its ordinary shares trade on the Nasdaq Global Select Market under the symbol PRTA. The report serves as a Regulation FD disclosure regarding specific equity compensation matters.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The filing discloses the existence of stock options held by certain directors and executive officers that are approaching expiration. These "Expiring Options" were granted in January, March, and April 2013 under the 2012 Long Term Incentive Plan and will expire in 2023 on their tenth anniversary.
- Total Shares Covered: Up to 458,174 ordinary shares.
- Ownership Percentage: Represents less than 1.0% of outstanding ordinary shares.
- Exercise Prices: Range from $6.41 to $6.73 per share.
Guidance, Outlook, and Management Commentary
Management has adopted Rule 10b5-1 trading plans to manage transactions related to these expiring options. The Company explicitly states that it does not undertake to report on future expiring options or modifications to trading plans unless required by law. The information provided is furnished, not filed, and is not intended to be incorporated by reference into registration statements.
Investor Verification Checklist
- Verify the current market price of PRTA shares relative to the $6.41–$6.73 exercise price range to assess the intrinsic value of the expiring options.
- Review subsequent Form 4 filings to confirm if and when directors or officers exercise these options under their Rule 10b5-1 plans.
- Confirm the total number of outstanding shares to validate the "less than 1.0%" ownership claim.
- Note that this filing contains no operational or financial updates; refer to the most recent 10-K or 10-Q for financial health.